Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q2 2026 (← Previous)

Filing Date: Aug 12, 2026

Total Value: $163M (100.0% shares, 0.0% debt)

Holdings (8)

Decreased Positions (1)

JBIO Jade Biosciences, Inc. 13.6%

Value $22.04M (+2.8%) Shares 991,783 (-35.0%) Est. Cost $33.31 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
JBIO	Jade Biosciences, Inc.	991,783 (-35.0%)	$22.04M (+2.8%)	13.6%	$33.31	—	Common Stock	008064206

Unchanged Positions (7)

GLUE Monte Rosa Therapeutics, Inc. 47.3%

Value $76.97M Shares 3,180,780 Est. Cost $7.50 Unrealized —

LENZ Lenz Therapeutics, Inc. 9.3%

Value $15.09M Shares 2,656,888 Est. Cost $36.77 Unrealized —

IPSC Century Therapeutics, Inc. 18.3%

Value $29.81M Shares 12,166,109 Est. Cost $1.94 Unrealized —

CTNM Contineum Therapeutics, Inc. 5.5%

Value $8.894M Shares 542,628 Est. Cost $16.10 Unrealized —

CRSP CRISPR Therapeutics AG 5.0%

Value $8.117M Shares 148,831 Est. Cost $40.26 Unrealized —

SKYE Skye Bioscience, Inc. 0.9%

Value $1.392M Shares 2,007,704 Est. Cost $7.75 Unrealized —

— Tempest Therapeutics, Inc. 0.2%

Value $299K Shares 269,772 Est. Cost $6.80 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
GLUE	Monte Rosa Therapeutics, Inc.	3,180,780	$76.97M	47.3%	$7.50	—	Common Stock	61225M102
LENZ	Lenz Therapeutics, Inc.	2,656,888	$15.09M	9.3%	$36.77	—	Common Stock	52635N103
IPSC	Century Therapeutics, Inc.	12,166,109	$29.81M	18.3%	$1.94	—	Common Stock	15673T100
CTNM	Contineum Therapeutics, Inc.	542,628	$8.894M	5.5%	$16.10	—	Common Stock	21217B100
CRSP	CRISPR Therapeutics AG	148,831	$8.117M	5.0%	$40.26	—	Common Shares	H17182108
SKYE	Skye Bioscience, Inc.	2,007,704	$1.392M	0.9%	$7.75	—	Common Stock	83086J200
—	Tempest Therapeutics, Inc.	269,772	$299K	0.2%	$6.80	—	Common Stock	87978U108